Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

NCT00230763 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Primary Open Angle (POAG)
Ocular Hypertension

Interventions

PROCEDURE: GSS questionnaire
PROCEDURE: IOP
DRUG: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
PROCEDURE: Visual acuity

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.